Current Research Studies

COPPER HISTIDINATE TREATMENT FOR MENKES DISEASE

CYP-001

Phase: N/A
Clinicaltrials.gov ID: NCT04074512

What is the goal of the study?

This study investigates the clinical effects and safety of subcutaneous Copper Histidinate treatment for patients diagnosed with Menkes disease and previously treated at NICHD under protocol 09-CH-0059 and newly diagnosed Menkes disease patients.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

PI (Study Doctor): Terry Kho
Study Team Member: Hayden Vreugdenhil, [email protected]